Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Modus Therapeutics Holding AB via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
2025-07-29 11:30:00
Modus Therapeutics’ Extraordinary General Meeting on 29 July 2025 resolved in accordance with the following:
- To amend the company’s articles of association in order to increase the limits of the company’s share capital and number of shares, whereby the share capital shall be not less than SEK 5,000,000 and not more than SEK 20,000,000, and the number of shares shall be not less than 100,000,000 and not more than 400,000,000.
- To approve the Board’s decision of 26 June 2025, regarding issuance of up to 8,984,724 units consisting of shares, warrants of series 2025/2026 and warrants of series 2025/2030 (the “Rights Issue”). The record date for participation in the Rights Issue is 8 August 2025. The right to subscribe for units shall be granted to the Modus Therapeutics’ shareholders, with one (1) existing share entitling the holder to one (1) unit right. The unit right entitles the holder to subscribe for new units with preferential rights. Four (4) unit rights entitle the holder to subscribe for one (1) unit. One (1) unit consists of nine (9) newly issued shares, three (3) warrants of series 2025/2026 and four (4) warrants of series 2025/2030. For further information regarding the Rights Issue, please refer to the previously published press release dated 26 June 2025.
- To authorise the Board to, for the period until the end of the next annual general meeting, on one or more occasions and with deviation from the shareholders’ preferential rights, resolve on new issue of shares and/or warrants. The right to subscribe for shares and/or warrants shall be primarily granted to those who have entered into guarantee undertakings to guarantee the Rights Issue announced by the Company on 26 June 2025, but also other potential investors who are not shareholders in the Company and who wish to invest in the Company in connection with the Rights Issue.